Table 1.
Baseline characteristics
| Variable | PU at baselinea (N = 60) | No PU at baselinea (N = 169) | Missing PU statusa (N = 1b) | Totalc |
|---|---|---|---|---|
| Age (years) | ||||
| Mean (SD) | 73.8 (15.9) | 72.1 (18.3) | – | 72.6 (17.6) |
| Median (range) | 76 (29, 98) | 78 (19,102) | 78 (N/A) | 77 (19, 102) |
| Sex, N (%) | ||||
| Male | 27 (27.3%) | 72 (72.7%) | 0 (0.0%) | 99 (43.0%) |
| Female | 33 (25.2%) | 97 (74.0%) | 1 (0.8%) | 131 (57.0%) |
| Ethnicity N (%) | ||||
| Caucasian | 58 (25.9%) | 165 (73.7%) | 1 (0.4%) | 224 (97.4%) |
| Other | 2 (33.3%) | 4 (66.7%) | 0 (0.0%) | 6 (2.6%) |
| Setting, N (%) | ||||
| Community | 37 (30.3%) | 84 (68.9%) | 1 (0.1%) | 122 (53.0%) |
| Secondary care hospital | 23 (21.3%) | 85 (78.7%) | 0 (0.0%) | 108 (47.0%) |
| Mobility status, PURPOSE‐T step 1, N (%) | ||||
| Walks independently with or without walking aids | 10 (12.7%) | 69 (87.3%) | 0 (0.0%) | 79 (34.3%) |
| Needs help of another person to walk | 6 (22.2%) | 21 (77.8%) | 0 (0.0%) | 27 (11.7%) |
| Spends all/majority of time in bed/chair | 16 (28.1%) | 40 (70.2%) | 1 (1.8%) | 57 (24.8%) |
| Remains in same position for long periods | 28 (42.4%) | 38 (57.6%) | 0 (0.0%) | 66 (28.7%) |
| Not completed | 0 (0.0%) | 1 (100%) | 0 (0.0%) | 1 (0.4%) |
| Braden score, N (%) | ||||
| At risk (≤18) | 35 (41.2%) | 50 (58.8%) | 0 (0.0%) | 85 (37.0%) |
| Not at risk (>18) | 25 (17.2%) | 119 (82.1%) | 1 (0.7%) | 145 (63.0%) |
| Waterlow total score | ||||
| At risk (≥10) | 60 (31.1%) | 132 (68.4%) | 1 (0.5%) | 193 (83.9%) |
| Not at risk (<10) | 0 (0.0%) | 37 (100%) | 0 (0.0%) | 37 (16.1%) |
| PURPOSE‐T risk categorization | ||||
| Secondary prevention/treatment pathway | 60 (83.3%) | 12 (16.7%) | 0 (0.0%) | 72 (31.3%) |
| Primary prevention pathway | 0 (0.0%) | 111 (100%) | 0 (0.0%) | 111 (48.3%) |
| Not currently at risk pathway | 0 (0.0%) | 46 (97.9%) | 1 (2.1%) | 47 (20.4%) |
a
Percentages in the PU status columns correspond to the proportion of patients within that characteristic who do (or do not) have a PU at baseline (e.g. 27.3% (27 out of 99) of the male population were observed to have a PU at baseline).
b
There was one community patient for whom their PU status at baseline could not be determined as there were no skin assessments recorded by the tissue viability team member.
c
Percentages in the total column correspond to the proportion of patients from the overall population with that characteristic (e.g. 43.0% of overall population were male; 57.0% female).